LXRX — LEXICON PHARMACEUTICALS INC (Healthcare >> Biotechnology)
LXRX FAQ
What is LXRX's P/E ratio?
LEXICON PHARMACEUTICALS INC (LXRX) currently trades at a P/E ratio of 258.16.
What is LXRX's ROE?
LEXICON PHARMACEUTICALS INC reports a Return on Equity (ROE) of -12.86%.
What is LXRX's dividend yield?
LEXICON PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is LXRX's Deepscope Quality Score?
Deepscope rates LXRX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LXRX?
Deepscope's AI Timing Score for LXRX is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LXRX belong to?
LEXICON PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.92
Price
0.03
(1.59%)
Day Change
|
|
|---|
LXRX Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.92 |
| PBV / Sector |
4.14 / 4.91
|
| Earning Per Share | -0.06 |
| PE / Sector |
258.16 / 18.34
|
| PEG or PE/Growth / Sector |
-11.15 / 0.61
|
| Average 1M Daily Value |
4.01 M
GREAT
|
| Average 1W Daily Value |
3.44 M
GREAT
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
47% |
| Lợi tức cho nhà đầu tư |
|
4% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-13 11:13:31 |
| Symbol | LXRX |
| Name | LEXICON PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 444.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 839.53 / 9,034.83 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2445 Technology Forest Boulevard, The Woodlands, TX, United States, 77381
Phone: 281 863 3000
Website: https://www.lexpharma.com
Employees: 81
Sector: Healthcare >> Biotechnology
Description: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google